Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUSB | P08236 | 2/20 | 0.40 |
| ▸ | EBP | Q15125 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 5/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 5/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 5/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | GLB1 | P16278 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25122649 | 0.91 | GUSB (0.44) | GUSBEBPSIGMAR1GNAI3GNAO1 | |
| SCHEMBL25707347 | 0.89 | GUSB (0.38) | GUSBEBPSIGMAR1GNAI3GNAO1 | |
| SCHEMBL25702065 | 0.86 | GUSB (0.41) | GUSBEBPSIGMAR1GNAI3GNAO1 | |
| SCHEMBL23807004 | 0.86 | GUSB (0.38) | GUSBEBPSIGMAR1GNAI3GNAO1 | |
| SCHEMBL25728746 | 0.85 | GUSB (0.37) | GUSBEBPSIGMAR1GNAI3GNAO1 | |
| SCHEMBL25884130 | 0.84 | GUSB (0.41) | GUSBEBPSIGMAR1GNAI3GNAO1 | |
| SCHEMBL25884563 | 0.84 | LMNA (0.38) | GUSBEBPSIGMAR1GNAI3GNAO1 | |
| SCHEMBL26405489 | 0.84 | LMNA (0.38) | GUSBEBPSIGMAR1GNAI3GNAO1 | |
| SCHEMBL25888000 | 0.83 | GUSB (0.40) | GUSBEBPSIGMAR1GNAI3GNAO1 | |
| SCHEMBL26478671 | 0.82 | GUSB (0.46) | GUSBEBPSIGMAR1GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GUSB 1746/4885EBP 3184/4885SIGMAR1 3199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.